Ischemic Memory Imaging With MCE
| Registry | NCT03009266 |
|---|---|
| Status | Unknown |
| Phase | Early Phase 1 |
| Study type | Interventional; non randomized, parallel, masking: none, diagnostic |
| Enrollment | 40 (Estimated) |
| Sponsor | Oregon Health and Science University (Other) |
| Conditions | Myocardial Ischemia |
| Interventions | Sonazoid (Drug) |
| Dates | start 2018-07-07, primary completion 2019-12-01 (estimated), completion 2019-12-01 (estimated), first posted 2017-01-04, last updated 2018-08-23 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Myocardial Ischemia All trials of Sonazoid
The overall aim of this study is to determine whether non-invasive imaging with myocardial contrast echocardiography using can provide information on the presence and spatial extent of recent myocardial ischemia by non-invasive echocardiographic imaging.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Normal controls | Experimental | Drug: Sonazoid | Normal controls who will undergo dose-ranging studies to determine the optimal dose of phosphatidylserine-containing microbubbles that does not produce delayed myocardial opacification on myocardial contrast echocardiography (MCE). |
| Patients with ACS | Experimental | Drug: Sonazoid | Subjects with ACS who have undergone primary percutaneous intervention in whom MCE with phosphatidylserine-containing microbubbles will be performed to determine whether the risk area can be detected and spatially defined. |
Sex: All, ages: 19 Years to 90 Years, accepts healthy volunteers
NORMAL CONTROL GROUP Inclusion Criteria: * Normal control individuals Exclusion Criteria: * History of cardiovascular disease (coronary artery disease, MI, peripheral artery disease) * allergy to eggs or ultrasound contrast agents * known or detected right to left shunt * presence of a wall motion abnormality * pregnancy ACS GROUP Inclusion Criteria: * Patients with diagnosis of acute coronary syndrome with either unstable angina or non-ST-elevation MI * Referred for primary percutaneous intervention * At least 1 high risk features (ST changes, positive troponin, wall motion abnormality) Exclusion Criteria: * allergy to eggs or ultrasound contrast agents * hemodynamic instability or shock * known or detected right to left shunt * pregnancy * multivessel CAD requiring multivessel PCI
| Facility | City | Country | Status |
|---|---|---|---|
| OHSU | Portland, Oregon | United States | Recruiting |